way 100635 has been researched along with butaclamol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brasili, L; Costantino, L; Franchini, S; Gandolfi, F; Leonardi, A; Poggesi, E; Prezzavento, O; Ronsisvalle, G; Sorbi, C; Vittorio, F | 1 |
| Andres-Mach, M; Czuczwar, S; Dawidowski, M; Herold, F; Kleps, J; Mazurek, A; Mazurek, AP; Nowak, G; Pluciński, F; Stachowicz, K; Stefanowicz, J; Szewczyk, B; Sławińska, A; Słowiński, T; Wolska, I; Łuszczki, JJ | 1 |
2 other study(ies) available for way 100635 and butaclamol
| Article | Year |
|---|---|
Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands.
Topics: Animals; Binding Sites; Biochemistry; Cells, Cultured; Drug Evaluation, Preclinical; Guinea Pigs; Humans; Inhibitory Concentration 50; Ligands; Piperazines; Piperidines; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Receptors, Opioid; Receptors, sigma; Serotonin 5-HT1 Receptor Agonists; Sigma-1 Receptor; Structure-Activity Relationship | 2005 |
Synthesis and biological investigation of potential atypical antipsychotics with a tropane core. Part 1.
Topics: Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Mice; Models, Molecular; Radioligand Assay; Rats; Receptors, Neurotransmitter; Structure-Activity Relationship; Tropanes | 2011 |